Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias.

Trial Profile

Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs LOR 2040 (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Nov 2012 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top